Publications by authors named "Amir Hessam Zare"
Background: Dabrafenib plus trametinib is a novel targeted therapy for low-grade (LGG) and high-grade (HGG) gliomas. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of dabrafenib plus trametinib in LGG and HGG gliomas.
Methods: The electronic databases of PubMed/Medline, Scopus, Embase, and Web of Science were searched from inception to 5 September 2024.
Background: The pRESET stent retriever is a self-expanding nitinol stent designed for mechanical thrombectomy in cases of large vessel occlusion during acute ischemic stroke. This systematic review and meta-analysis synthesize the available evidence on the safety and efficacy of the pRESET device.
Methods: This is a systematic review and meta-analysis study conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Article Synopsis
- The SMART coil system is a new type of embolic coil used to treat cerebral aneurysms, involving a platinum coil and a detachment mechanism.
- A study analyzing data from 7 research articles found varying rates of aneurysm occlusion and residuals post-treatment, with a 45% complete occlusion rate and significant long-term success at 66%.
- Overall, the SMART coil system is suggested to be both safe and effective, with low rates of adverse events compared to other treatment options.
Background: Regarding the newly diagnosed vestibular schwannomas (VSs), active surveillance, microsurgical resection (MS), and stereotactic radiosurgery (SRS) are the leading treatment options. Although SRS is an effective intervention with a low incidence of complications, failure may occur occasionally. Several options, including repeat SRS, are considered salvage treatment after failure of the SRS.
View Article and Find Full Text PDFIs add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
Neurosurg Rev
August 2024
Article Synopsis
- * The combination treatment leads to modest improvements in overall survival (OS) rates, with 2-year OS at 39% for those receiving bevacizumab versus 20% for standard therapy alone.
- * Despite potential benefits, the treatment is associated with a 62% incidence of adverse events, including significant complications like fatigue and CNS hemorrhage, highlighting the need for careful patient